1
2
3
Cytokinetics Inc (NASDAQ)
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
交易时间表 (UTC)
开放
立即关闭
关闭日期
开幕日期
于
-
这将显示您所在时区的开放时间
(UTC)
滴答声 | CYTK |
合同价值 | 100 shares |
最大杠杆率 | 1:5 |
掉期历史
日期 | Short Swap (%) | Long Swap (%) | 无数据 |
---|
最低交易量 | 0.01 地段 |
最大交易量 | 100 地段 |
套期保值保证金 | 50% |